SAM-e Behavioral-related Adverse E!ects
In addition to the 14 placebo-controlled studies
in patients with depressive symptoms, three
placebo-controlled studies in fibromyalgia were
identified.121-123 All 17 publications were scrutinized
for reports of AEs of interest (i.e., suicidality
or other behavioral-related events). !e results are
summarized in Table 9. Again, as was the case with
most SJW studies, generally very little specific AE
information was included. Using the previously
described approaches for including AE findings,
five of 17 studies included complete AE reporting,
five included partial AE information, and seven did
not provide any specific AE information. Only a
few instances of specific behavioral-related AEs
were mentioned, with no evidence for the occurrence
of treatment-emergent suicidality detected.
Four study publications mentioned AEs of mania/
hypomania or psychomotor excitation following
SAM-e administration (no similar AEs were
reported for placebo in those studies). In two
studies, a greater incidence of anxiety-related AEs
was reported for SAM-e than for placebo.